It’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
Valbiotis appoints Josep Infesta
AppointmentsValbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development.
The great green rush
BackgroundIt’s the most commonly cultivated, trafficked and abused illicit drug worldwide, and there’s still a lot of social stigma attached to the recreational use of pot. But it’s slowly dawning on regulators in countries from Canada to the US to South Africa that by ignoring the clear medical benefits of marijuana, they may have thrown the baby out with the bathwater. Countries across Europe are now also opening their minds, laws and wallets to cannabis.
UK launches new payment model for antimicrobials
Latest NewsIn order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
BioNtech swallows MAB Discovery antibody unit
Latest NewsImmunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discovery‘s antibody generation unit.
Clariant inks cellulosic biodiesel pact with ExxonMobil/REG
Latest NewsSwiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
IMI launches €80m call
Latest NewsThe Innovative Medicines Initiative II has earmarked €80m for pre-competetive research improving the pharmaceutical industry’s productivity.
AMR: Novo Holdings funds companies with €18m
Latest NewsAsceneuron appoints Peter Van Vlasselaer
AppointmentsAsceneuron, a company in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors.
CJEU ruling triggers exodus of EU plant research
BackgroundAccording to a brand-new EU-wide survey, European plant researchers are concerned about the European Court of Justices (CJEU) interpretation that targeted mutation methods aimed at improving crop yield and resistance to climate change yield GMOs. In an open letter, they call for political action and a modernisation of the EU Directive 2001/18/EC because a lack in tech-transfer would put Europe at the bottom of the pile in the upcoming bioeconomy.
Boehringer expands neurology activities
Latest NewsBoehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.